## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 12.4% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($43.08)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Centene Jumps 16.3% in 3 Months: A Comeback or Calm Before the Storm?**
- Source: Finviz | 20260106T171948 | Somewhat-Bullish | Relevance: 100%
- Centene Corporation's shares have risen 16.3% in three months, outperforming its industry, despite significant operating expense increases and a narrowing net margin in 2025. While challenges remain, including high medical costs and debt, the company's expanding commercial business and expected earnings recovery in 2026 offer some long-term support. The stock, currently with a Zacks Rank #3 (Hold), is seen as a selective value for patient investors.

**2. Centene Earnings Preview: What to Expect**
- Source: inkl | 20260106T120748 | Neutral | Relevance: 100%
- Centene (CNC) is expected to release its fourth-quarter earnings report soon, with analysts forecasting a non-GAAP loss of $1.25 per share. Despite an anticipated decline in EPS for fiscal 2025, a significant rebound is projected for fiscal 2026. The stock recently received an "Overweight" upgrade from Barclays due to improving prospects in the Affordable Care Act market, although the overall analyst consensus remains a "Hold."

**3. Centene Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20260105T163000 | Bullish | Relevance: 100%
- Centene Corp. (CNC) shares rose 6.94% to $44.68, outperforming the S&P 500 Index (SPX) and the Dow Jones Industrial Average (DJIA) on a favorable trading day for the stock market. This marked the stock's second consecutive day of gains.

**4. Barclays upgrades Centene stock rating to Overweight on ACA margin upside**
- Source: Investing.com | 20260105T112027 | Bullish | Relevance: 100%
- Barclays has upgraded Centene (NYSE:CNC) from Equalweight to Overweight and raised its price target to $54.00, citing potential margin improvements in the company's Affordable Care Act (ACA) exchange business. The upgrade is based on Centene's strong premium increases and stable competitive positioning expected to lead to 2.0% ACA margins by 2026, exceeding Street estimates for EPS in 2026 and 2027. Despite past challenges, Centene's financial health is rated "GREAT" by InvestingPro.

**5. Barclays Upgrades Centene (CNC) with Raised Price Target | CNC S**
- Source: GuruFocus | 20260105T134304 | Bullish | Relevance: 100%
- Barclays has upgraded Centene (CNC) from "Equal-Weight" to "Overweight," raising its price target from $44.00 to $54.00, a 22.73% increase. Centene, a managed care organization focusing on government-sponsored healthcare plans, currently has an average brokerage recommendation of "Hold." GuruFocus estimates Centene's fair value (GF Value) at $100.66, suggesting a significant upside from its current price.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $54 | $44 | +23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +8.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.69 elevated, pricing in significant growth expectations. Forward P/E 15.8x attractive for 42% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (1 raises, avg +23%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.5B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.69 |
| Forward P/E | 15.8 |
| Current P/E | 22.5 |
| YoY Growth | 42.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 4.3% to 12.4% (+8.1% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (12.4% > 10.0%), caution on chasing. MRS_5 at 5.8% confirms short-term momentum alignment. AM_20 at 13.3% shows strong absolute momentum above own 20MA. Outperforming sector by 10.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 78, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 12.36% (CS: 97) | Strong |
| RSI_14 | 78.1 | Overbought |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.133x | Above |
| vs SMA50 | 1.199x | Above |
| vs SMA200 | 1.074x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $45.74
- **Stop Loss:** $43.08 (5.8% risk)
- **Target:** $48.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 496
- **Position Value:** $22,687.04
- **Portfolio %:** 22.69%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*